Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics - Open

Open Access 05-03-2024 | Tuberous Sclerosis | Original Research Article

A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales

Authors: Colin Burke, Catriona Crossan, Emma Tyas, Matthew Hemstock, Dawn Lee, Sally Bowditch

Published in: PharmacoEconomics - Open

Login to get access

Abstract

Objectives

The aim of this study was to evaluate the cost effectiveness of plant-derived highly purified cannabidiol (Epidyolex® in the UK; 100 mg/mL oral solution) as an add-on treatment to usual care for the management of treatment-refractory seizures associated with tuberous sclerosis complex (TSC) in patients aged ≥ 2 years.

Methods

A cohort-based model was developed using a National Health Service perspective and lifetime horizon. Health states were based on weekly seizure frequency and seizure-free days, utilizing patient-level data from the GWPCARE6 trial (ClinicalTrials.gov identifier: NCT02544763). Two independent regression models were applied to individual patient-level data to predict seizure-free days and seizure frequency. Healthcare resource utilization data were sourced from a Delphi panel, and patient and caregiver health-related quality of life values were elicited using vignettes valued by the general public. Outcomes relating to TSC-associated neuropsychiatric disorders were modeled with costs and quality-adjusted life-years sourced from published literature.

Results

In the base case, compared with usual care alone, 12 mg/kg/day cannabidiol was associated with an incremental cost-effectiveness ratio (ICER) of £23,797. The National Institute for Health and Care Excellence disease severity modifier reduced the ICER to £19,831. Probabilities of cost effectiveness at willingness-to-pay thresholds of £20,000 and £30,000 were 30% and 52%, respectively, for the base case and 39% and 66%, respectively, for the disease severity modifier. Results were robust to sensitivity and scenario analyses.

Conclusions

At 12 mg/kg/day and an ICER threshold of £20,000–£30,000, we provide evidence for the cost effectiveness of add-on cannabidiol treatment for patients with TSC-associated seizures aged ≥ 2 years who are refractory to current treatment.
Appendix
Available only for authorised users
Literature
1.
Staley BA, Vail EA, Thiele EA. Tuberous sclerosis complex: diagnostic challenges, presenting symptoms, and commonly missed signs. Pediatrics. 2011;127:e117–25.PubMedCrossRef
2.
3.
Webb DW, Fryer AE, Osborne JP. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol. 1996;38:146–55.PubMedCrossRef
4.
Devlin LA, Shepherd CH, Crawford H, Morrison PJ. Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland. Dev Med Child Neurol. 2006;48:495–9.PubMedCrossRef
5.
Welin K-O, Carlqvist P, Svensson A, Althin R, Eklund E, Rask O. Epilepsy in tuberous sclerosis patients in Sweden – healthcare utilization, treatment, morbidity, and mortality using national register data. Seizure. 2017;53:4–9.PubMedCrossRef
6.
Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. Epilepsy in tuberous sclerosis complex: findings from the TOSCA study. Epilepsia Open. 2018;4:73–84.PubMedPubMedCentralCrossRef
7.
Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51:1236–41.PubMedCrossRef
8.
Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. Lancet Neurol. 2015;14:733–45.PubMedCrossRef
9.
Shehata HS, AbdelGhaffar HM, Nasreldin M, Elmazny A, Abdelalim A, Sabbah A, et al. Clinical patterns and outcomes of status epilepticus in patients with tuberous sclerosis complex. Ther Clin Risk Manag. 2017;13:779–85.PubMedPubMedCentralCrossRef
10.
Zöllner JP, Franz DN, Hertzberg C, Nabbout R, Rosenow F, Sauter M, et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis. 2020;15:23.PubMedPubMedCentralCrossRef
11.
de Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13:157.PubMedPubMedCentralCrossRef
12.
Amin S, Mallick AA, Lux A, O’Callaghan F. Quality of life in patients with tuberous sclerosis complex (TSC). Eur J Paediatr Neurol. 2019;23:801–7.PubMedCrossRef
13.
Willems LM, Schubert-Bast S, Grau J, Hertzberg C, Kurlemann G, Wiemer-Kruel A, et al. Health-related quality of life in children and adolescents with tuberous sclerosis complex and their caregivers: a multicentre cohort study from Germany. Eur J Paediatr Neurol. 2021;35:111–22.PubMedCrossRef
14.
Schubert-Bast S, Strzelczyk A. Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. Ther Adv Neurol Disord. 2021;14:17562864211031100.PubMedPubMedCentralCrossRef
15.
Winterkorn EB, Pulsifer MB, Thiele EA. Cognitive prognosis of patients with tuberous sclerosis complex. Neurology. 2007;68:62–4.PubMedCrossRef
16.
Jozwiak S, Kotulska K, Domańska-Pakieła D, Chmielewski D, Borkowska J, Kuczynski D, et al. Early epilepsy, and not cortical tubers, determines mental retardation in infants with TSC: prospective studies. J Neurol Sci. 2009;285:S252 (Abstract PO18-WE-30).
17.
Vignoli A, Turner K, La Briola F, Piazzini A, Zambrelli E, Chiesa V, et al. Neuropsychological outcomes in adults with tuberous sclerosis complex. Epilepsia. 2012;53(Suppl. 5):214 (Abstract p736).
18.
Bhatt R, Hellemann G, Varcin K, Nelson C, Jeste S, Sahin M, et al. Epilepsy and cognition in infants with tuberous sclerosis complex: can early identification of epilepsy severity yield better cognitive outcomes? Neurology. 2016;86(Suppl. 16):P5.151 (Abstract).
19.
Capal JK, Bernardino-Cuesta B, Horn PS, Murray D, Byars AW, Bing NM, et al. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017;70:245–52.PubMedPubMedCentralCrossRef
20.
Gupta A, de Bruyn G, Tousseyn S, Krishnan B, Lagae L, Agarwal N, et al. Epilepsy and neurodevelopmental comorbidities in tuberous sclerosis complex: a natural history study. Pediatr Neurol. 2020;106:10–6.PubMedCrossRef
21.
Bombardieri R, Pinci M, Moavero R, Cerminara C, Curatolo P. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010;14:146–9.PubMedCrossRef
22.
Vergeer M, Ranitz-Greven WL, Neary MP, Ionescu-Ittu R, Emond B, Sheng Duh M, et al. Epilepsy, impaired functioning, and quality of life in patients with tuberous sclerosis complex. Epilepsia Open. 2019;4:581–92.PubMedPubMedCentralCrossRef
23.
Shepherd C, Koepp M, Myland M, Patel K, Miglio C, Siva V, et al. Understanding the health economic burden of patients with tuberous sclerosis complex (TSC) with epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink (CPRD). BMJ Open. 2017;7: e015236.PubMedPubMedCentralCrossRef
24.
Strzelczyk A, Rosenow F, Zöllner JP, Simon A, Wyatt G, Holland R, et al. Epidemiology, healthcare resource use, and mortality in patients with tuberous sclerosis complex: a population-based study on German health insurance data. Seizure. 2021;91:287–95.PubMedCrossRef
25.
Auvin S, Damera V, Martin M, Holland R, Simontacchi K, Saich A. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome. Epilepsy Behav. 2021;123: 108239.PubMedCrossRef
26.
Overwater IE, Heus KB, Rietman AB, ten Hoopen LW, Vergouwe Y, Moll HA, et al. Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs. Epilepsia. 2015;56:1239–45.PubMedCrossRef
27.
McDonald A, Goodwin J, Roberts S, Fish L, Vaughan B, Cooper A, et al. “We’ve made the best of it. But we do not have a normal life”: families’ experiences of tuberous sclerosis complex and seizure management. J Intellect Disabil Res. 2019;63:947–56.
28.
Parthasarathy S, Mahalingam R, Melchiorre J, Harowitz J, Devinsky O. Mortality in tuberous sclerosis complex. Epilepsy Behav. 2021;121: 108032.PubMedCrossRef
29.
30.
31.
Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, et al. Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial. JAMA Neurol. 2021;78:285–92.PubMedCrossRef
32.
33.
34.
35.
36.
37.
Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol. 2007;64:1595–9.PubMedCrossRef
38.
39.
Bonadt K, Bowditch S. Real-World Dosierung von Cannabidiol (CBD) bei Patientinnen und Patienten mit wahrscheinlichem Lennox-Gastaut-Syndrom, Dravet-Syndrom und Tuberösem Sklerose Komplex: Eine retrospektive Studie zu deutschen Apothekenabrechnungsdaten. Zeitschrift für Epileptologie. 2023;36:1–107 (Abstract p86).
40.
Thiele EA, Bebin EM, Filloux F, Kwan P, Loftus R, Sahebkar F, et al. Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: an open-label extension trial. Epilepsia. 2022;63:426–39.PubMedCrossRef
41.
Wu JY, Cock HR, Devinsky O, Joshi C, Miller I, Roberts CM, et al. Time to onset of cannabidiol (CBD) treatment effect and resolution of adverse events in tuberous sclerosis complex: post hoc analysis of randomized controlled Phase 3 trial GWPCARE6. Epilepsia. 2022;63:1189–99.PubMedPubMedCentralCrossRef
42.
Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol. 2020;77:613–21.PubMedCrossRef
43.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378:1888–97.PubMedCrossRef
44.
45.
46.
47.
Amin S, Lux A, Calder N, Laugharne M, Osborne J, O’Callaghan F. Causes of mortality in individuals with tuberous sclerosis complex. Dev Med Child Neurol. 2017;59:612–7.PubMedCrossRef
48.
Lo SH, Marshall J, Skrobanski H, Lloyd A. Patient and caregiver health state utilities in tuberous sclerosis complex. Pharmacoecon Open. 2022;6:105–21.PubMedCrossRef
49.
Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Soft. 2015;67:1–48.CrossRef
50.
51.
Srivastava T, Latimer NR, Tappenden P. Estimation of transition probabilities for state-transition models: a review of NICE appraisals. Pharmacoeconomics. 2021;39:869–78.PubMedCrossRef
52.
Thiele E, Marsh E, Mazurkiewicz-Beldzinska M, Halford JJ, Gunning B, Devinsky O, et al. Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study. Epilepsia. 2019;60:419–28.PubMedPubMedCentralCrossRef
53.
Halford JJ, Scheffer I, Nabbout R, Sanchez-Carpintero R, Malawky YS, Wong M, et al. Long-term safety and efficacy of cannabidiol (CBD) treatment in patients with Dravet syndrome (DS): 3-year interim results of an open-label extension (OLE) trial (GWPCARE5). Neurology. 2020;94(Suppl. 15):439 (Abstract).
54.
Patel A, Chin R, Mitchell W, Perry S, Weinstock A, Checketts D, et al. Long-term safety and efficacy of cannabidiol (CBD) treatment in patients with Lennox Gastaut syndrome (LGS): 3-year results of an open-label extension (OLE) trial (GWPCARE5). Neurology. 2020;94(Suppl. 15):668 (Abstract).
55.
Weinstock A, Bebin EM, Checketts D, Clark G, Szaflarski J, Seltzer L, et al. Long-term efficacy and safety of cannabidiol (CBD) in patients with tuberous sclerosis complex (TSC): 4-year results from the expanded access program (EAP). Neurology. 2021;96(Suppl. 15):2405 (Abstract).
56.
57.
58.
59.
60.
61.
62.
63.
Myland M, Buysse B, Tsong W, Power GS, Nordli D, Chin RF. Seizure frequency, healthcare resource utilisation and mortality in childhood epilepsy: a retrospective cohort study using the THIN database. Arch Dis Child. 2019;104:1070–6.PubMedCrossRef
64.
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:718–79.PubMedCrossRef
65.
de Kinderen RJ, Wijnen BF, van Breukelen G, Postulart D, Majoie MH, Aldenkamp AP, et al. From clinically relevant outcome measures to quality of life in epilepsy: a time trade-off study. Epilepsy Res. 2016;125:24–31.PubMedCrossRef
66.
Kirkham FJ, Vigevano F, Raspall-Chaure M, Wilken B, Lee D, Le Reun C, et al. Health-related quality of life and the burden of prolonged seizures in noninstitutionalized children with epilepsy. Epilepsy Behav. 2020;102:106340.PubMedCrossRef
67.
Ten Hoopen LW, de Nijs PF, Duvekot J, Greaves-Lord K, Hillegers MH, Brouwer WB, et al. Children with an autism spectrum disorder and their caregivers: capturing health-related and care-related quality of life. J Autism Dev Disord. 2020;50:263–77.PubMedCrossRef
68.
van der Kolk A, Bouwmans CA, Schawo SJ, Buitelaar JK, van Agthoven M, Hakkaart-van Roijen L. Association between societal costs and treatment response in children and adolescents with ADHD and their parents. A cross-sectional study in the Netherlands. Springerplus. 2015;4:224.
69.
Johansson R, Carlbring P, Heedman Å, Paxling B, Andersson G. Depression, anxiety and their comorbidity in the Swedish general population: point prevalence and the effect on health-related quality of life. PeerJ. 2013;1:e98.PubMedPubMedCentralCrossRef
70.
Tritton T, Bennett B, Brohan E, Grant L, Cooper A, Fladrowski C, et al. Health utilities and quality of life in individuals with tuberous sclerosis complex (TSC) who experience epileptic seizures: a web-based survey. Epilepsy Behav. 2019;92:213–20.PubMedCrossRef
71.
Villanueva V, García-Ron A, Smeyers P, Arias E, Soto V, García-Peñas JJ, et al. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy. Epilepsy Behav. 2022;137:108958.PubMedCrossRef
72.
Contin M, Mohamed S, Santucci M, Lodi MAM, Russo E, Mecarelli O, et al. Cannabidiol in pharmacoresistant epilepsy: clinical pharmacokinetic data from an expanded access program. Front Pharmacol. 2021;12: 637801.PubMedPubMedCentralCrossRef
73.
Wijnen B, Armstrong N, Ramaekers B, Witlox W, Westwood M, Fayter D, et al. Cannabidiol for adjuvant treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2020;38:1043–53.PubMedCrossRef
74.
Elliott J, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, et al. Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev. 2019;8:75.PubMedPubMedCentralCrossRef
75.
Neuberger EE, Carlson JJ, Veenstra DL. Cost-effectiveness of cannabidiol adjunct therapy versus usual care for the treatment of seizures in Lennox-Gastaut syndrome. Pharmacoeconomics. 2020;38:1237–45.PubMedCrossRef
76.
Hollenack K, Marshall J. Comment on “Cost-effectiveness of cannabidiol adjunct therapy versus usual care for the treatment of seizures in Lennox-Gastaut syndrome.” Pharmacoeconomics. 2021;39:473–5.PubMedPubMedCentralCrossRef
77.
Neuberger EE, Carlson JJ, Veenstra DL. Authors’ reply to Comment on “Cost-effectiveness of cannabidiol adjunct therapy versus usual care for the treatment of seizures in Lennox-Gastaut syndrome.” Pharmacoeconomics. 2021;39:477–8.PubMedCrossRef
78.
Abu-Sawwa R, Chase A, Fowowe O, Park Y. Effects of Epidiolex® (cannabidiol) on seizure-related emergency department visits and hospital admissions: a retrospective cohort study. Epilepsy Behav. 2022;127:108538.PubMedCrossRef
79.
Sullivan J, Specchio N, Devinsky O, Auvin S, Perry MS, Strzelczyk A, et al. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: a time-to-event analysis. Epilepsia. 2022;63:130–8.PubMedCrossRef
80.
Fallah A, Weil AG, Wang S, Lewis E, Baca CB, Mathern GW. Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with tuberous sclerosis complex. Epilepsy Behav. 2016;63:79–88.PubMedCrossRef
81.
de Vries PJ, Franz DN, Curatolo P, Nabbout R, Neary M, Herbst F, et al. Measuring health-related quality of life in tuberous sclerosis complex—psychometric evaluation of three instruments in individuals with refractory epilepsy. Front Pharmacol. 2018;9:964.PubMedPubMedCentralCrossRef
82.
Wijnen BF, Mosweu I, Majoie MH, Ridsdale L, de Kinderen RJ, Evers SM, et al. A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. Eur J Health Econ. 2018;19:861–70.PubMedCrossRef
83.
Simoens S. Using the Delphi technique in economic evaluation: time to revisit the oracle? J Clin Pharm Ther. 2006;31:519–22.PubMedCrossRef
Metadata
Title
A Cost-Utility Analysis of Add-On Cannabidiol Versus Usual Care Alone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex in England and Wales
Authors
Colin Burke
Catriona Crossan
Emma Tyas
Matthew Hemstock
Dawn Lee
Sally Bowditch
Publication date
05-03-2024
Publisher
Springer International Publishing
Published in
PharmacoEconomics - Open
Print ISSN: 2509-4262
Electronic ISSN: 2509-4254
DOI
https://doi.org/10.1007/s41669-024-00474-x